文献速递心血管MRDSA

基于EuroCMR/SPINS登记研究的12个医疗体系心脏血运重建成本最小化分析

Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS Registries.
PubMed 文献 · JACC Cardiovasc Imaging · 2022-01-12

基于EuroCMR(n=3647,59中心,18国)和SPINS(n=2349,13中心,11州)登记研究,在12个医疗体系比较CMR+CXA策略与CXA+FFR及单纯CXA策略的成本。CMR+CXA较CXA+FFR在所有体系均节省成本(低危42%±20%和52%±15%至高危31%±16%),较单纯CXA节省更高(63%±11%、73%±6%、52%±9%)。

要点

  • CMR+CXA策略在12个医疗体系中较CXA+FFR策略一致节省成本,低危患者节省42%±20%和52%±15%,高危节省31%±16%。
  • CMR+CXA策略较单纯CXA策略节省更高,低危患者分别节省63%±11%和73%±6%,高危节省52%±9%。
  • 所有组与0比较P<0.0001,成本节省在整个风险谱中一致。

核心结论

  • 在12个医疗体系中,CMR+CXA策略较假设的CXA+FFR策略在整个风险谱中产生一致的中度至高度成本节省,较单纯CXA策略在所有风险组中节省一致较高。

研究设计与样本

  • 基于EuroCMR登记研究(n=3647,59中心,18国)和SPINS登记研究(n=2349,13中心,11州)的成本最小化分析,覆盖12个医疗体系(欧洲8个、美国、拉丁美洲2个、亚洲1个),成本包括诊断检查(CMR和X线冠状动脉造影伴或不伴FFR)、血运重建及1年随访并发症,并行7个亚组分析覆盖低至高危队列。

诊断标准与关键数值

  • CMR+CXA策略中,缺血阳性CMR患者由治疗医师酌情行CXA和血运重建。
  • 假设的CXA+FFR策略中,对狭窄≥50%的血管行初始CXA和FFR,假设血运重建和并发症比例与CMR+CXA策略相同,FFR阳性率采用已发表研究数据。
  • 单纯CXA策略中,成本包括CXA和对狭窄≥50%病变的血运重建。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to compare the costs of a noninvasive cardiac magnetic resonance (CMR)-guided strategy versus 2 invasive strategies with and without fractional flow reserve (FFR).

BACKGROUND: Coronary artery disease (CAD) is a major contributor to the public health burden. Stress perfusion CMR has excellent accuracy to detect CAD. International guidelines recommend as a first step noninvasive testing of patients in stable condition with known or suspected CAD. However, nonadherence in routine clinical practice is high.

METHODS: In the EuroCMR (European Cardiovascular Magnetic Resonance) registry (n = 3,647, 59 centers, 18 countries) and the U.S.-based SPINS (Stress-CMR Perfusion Imaging in the United States) registry (n = 2,349, 13 centers, 11 states), costs were calculated for 12 health care systems (8 in Europe, the United States, 2 in Latin America, and 1 in Asia). Costs included diagnostic examinations (CMR and x-ray coronary angiography [CXA] with and without FFR), revascularizations, and complications during 1-year follow-up. Seven subgroup analyses covered low- to high-risk cohorts. Patients with ischemia-positive CMR underwent CXA and revascularization at the treating physician's discretion (CMR+CXA strategy). In the hypothetical invasive CXA+FFR strategy, costs were calculated for initial CXA and FFR in vessels with ≥50% stenoses, assuming the same proportion of revascularizations and complications as with the CMR+CXA strategy and FFR-positive rates as given in the published research. In the CXA-only strategy, costs included CXA and revascularizations of ≥50% stenoses.

RESULTS: Consistent cost savings were observed for the CMR+CXA strategy compared with the CXA+FFR strategy in all 12 health care systems, ranging from 42% ± 20% and 52% ± 15% in low-risk EuroCMR and SPINS patients with atypical chest pain, respectively, to 31% ± 16% in high-risk SPINS patients with known CAD (P < 0.0001 vs 0 in all groups). Cost savings were even higher compared with CXA only, at 63% ± 11%, 73% ± 6%, and 52% ± 9%, respectively (P < 0.0001 vs 0 in all groups).

CONCLUSIONS: In 12 health care systems, a CMR+CXA strategy yielded consistent moderate to high cost savings compared with a hypothetical CXA+FFR strategy over the entire spectrum of risk. Cost savings were consistently high compared with CXA only for all risk groups.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Moschetti, Kwong, Petersen, et al. Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS Registries. JACC Cardiovasc Imaging. 2022. PMID: 35033498. doi:10.1016/j.jcmg.2021.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。